



**ASX Announcement**

**29 August 2025**

## **Atomo Investor Webinar Presentation**

SYDNEY Australia, 29 August 2025 – Atomo Diagnostics Limited (ASX: **AT1**) (**Atomo** or the **Company**) has released its FY25 Results today.

A results briefing webinar for analysts and investors, hosted by Managing Director & CEO, John Kelly & Financial Controller, Suzy Elhlou will be held on Tuesday, 2<sup>nd</sup> September 2025 at 11.00am (AEST).

To access the webinar please pre-register by clicking [this link](#).

A copy of the FY25 investor presentation and Appendix 4E and Annual Report can be accessed through the following link: <https://investors.atomodiagnostics.com/announcements>

~ ENDS ~

**For more information, please contact:**

**John Kelly**  
Managing Director & CEO  
e. [john.kelly@atomodiagnostics.com](mailto:john.kelly@atomodiagnostics.com)  
p. +61 401 922 279

**Investor Queries**  
[investorqueries@atomodiagnostics.com](mailto:investorqueries@atomodiagnostics.com)

*This announcement was authorised by the Managing Director & CEO.*

### **About Atomo**

Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health. See more at [www.atomodiagnostics.com](http://www.atomodiagnostics.com)